ERAS

NEW ORLEANS, July 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Erasca, Inc. (NasdaqGS: ERAS) (“Erasca” or the “Company”), if they purchased or otherwise acquired the Company's securities between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Erasca between January 14, 2025 and April 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) investors of the  August 10, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Erasca Class Action Lawsuit : Do you, or did you, own shares of Erasca, Inc. (NASDAQ: ERAS)?

SAN FRANCISCO, July 9, 2026 /PRNewswire/ -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.

SAN DIEGO, July 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026, both dates inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the Erasca class action lawsuit. Captioned Cheng v.

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 8, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) of a class action securities lawsuit.

NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

New York, New York--(Newsfile Corp. - July 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. SO WHAT: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SAN FRANCISCO, July 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.

Bragar Eagel & Squire, P.C.  Litigation Partners  Brandon Walker  and Melissa Fortunato Encourage Investors Who Suffered Losses In Erasca (ERAS) To Contact Them Directly To Discuss Their Options